Edition:
United States

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

2,016JPY
20 Apr 2018
Change (% chg)

¥0 (+0.00%)
Prev Close
¥2,016
Open
¥2,009
Day's High
¥2,027
Day's Low
¥1,990
Volume
1,038,800
Avg. Vol
1,555,253
52-wk High
¥2,034
52-wk Low
¥1,397

Latest Key Developments (Source: Significant Developments)

Sumitomo Dainippon Pharma says change of president
Friday, 23 Feb 2018 01:53am EST 

Feb 23 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it appoints Masayo Tada as chairman of the board, and Hiroshi Nomura as president, effective April 1 .  Full Article

Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement
Friday, 16 Feb 2018 05:33pm EST 

Feb 16 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>::INTERCEPT PHARMA SAYS ON FEB 13, CO, SUMITOMO DAINIPPON PHARMA ENTERED INTO AMENDMENT TO CERTAIN LICENSE AGREEMENT DATED AS OF MARCH 29, 2011.INTERCEPT PHARMACEUTICALS INC - UNDER AMENDMENT, SUMITOMO DAINIPPON AGREED TO RETURN RIGHTS TO DEVELOP AND COMMERCIALIZE OCA IN JAPAN AND KOREA.INTERCEPT PHARMA - AGREED TO FOREGO ANY FURTHER MILESTONE OR ROYALTY PAYMENTS RELATING TO DEVELOPMENT AND COMMERCIALIZATION OF OCA IN JAPAN AND KOREA.INTERCEPT PHARMA - SUMITOMO DAINIPPON WAIVED RIGHTS TO COUNTRY OPTION, PARTIES ADJUSTED CERTAIN MILESTONE PAYMENT OBLIGATIONS REGARDING OCA.INTERCEPT PHARMA - SUMITOMO MAY CHOOSE TO PAY CO MILESTONE PAYMENT OR TERMINATE DEAL IF CERTAIN CLINICAL MILESTONES IN CHINA NOT MET BY DEC 31, 2020.  Full Article

Sumitomo Dainippon Pharma files patent infringement lawsuits regarding lATUDA® in U.S.
Wednesday, 14 Feb 2018 12:20am EST 

Feb 14 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it filed patent infringement lawsuits jointly with its U.S. subsidiary, Sunovion Pharmaceuticals Inc. on February 13(U.S. Eastern Time) in the U.S. District Court for the District of New Jersey against Emcure Pharmaceuticals Ltd. and in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC regarding their submissions of Abbreviated New Drug Applications for generic copies of LATUDA®(lurasidone HCl tablets).  Full Article

Sumitomo Dainippon Pharma says result of early-retirement program
Sunday, 24 Dec 2017 09:25pm EST 

Dec 25 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T> ::Says 86 employees took up the offer of the early-retirement program announced on Sept. 27.Effective date of retirement is March 31, 2018.A premium will be added to the normal retirement allowance of eligible applicants.Says eligible applicants will also have the option to receive job-placement assistance.  Full Article

Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD
Tuesday, 5 Dec 2017 08:48pm EST 

Dec 5 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>::SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD.SUNOVION EXPECTS LONHALA MAGNAIR TO BE AVAILABLE IN U.S. PHARMACIES IN EARLY 2018.SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD.  Full Article

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe
Tuesday, 21 Nov 2017 02:32am EST 

Nov 21 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co .Under the terms of the agreement, Sunovion Pharmaceuticals Europe Ltd., a subsidiary company of Sumitomo Dainippon Pharma Group, has granted Angelini exclusive commercialization rights for LATUDA in 29 European countries and in Turkey.  Full Article

Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin
Monday, 30 Oct 2017 03:06am EDT 

Oct 30 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.Under the Agreement, Poxel SA is entitled to receive an upfront payment of approximately 4.75 billion yen and future potential development milestone payments of up to 2.75 billion yen .  Full Article

Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia
Monday, 30 Oct 2017 02:30am EDT 

Oct 30 (Reuters) - POXEL SA ::SUMITOMO DAINIPPON PHARMA AND POXEL ANNOUNCE STRATEGIC PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN, CHINA AND ELEVEN OTHER ASIAN COUNTRIES.‍POXEL AND SUMITOMO DAINIPPON PHARMA TO JOINTLY DEVELOP IMEGLIMIN FOR TREATMENT OF TYPE 2 DIABETES IN JAPAN,​.‍SUMITOMO DAINIPPON PHARMA ASSUMES PHASE 3 AND COMMERCIALIZATION COSTS​.‍POXEL RECEIVES AN UPFRONT PAYMENT OF ¥4.75 BILLION (APPROXIMATELY EUR 36 MILLION, $42 MILLION)​.‍SUMITOMO DAINIPPON PHARMA SOLELY RESPONSIBLE FOR IMEGLIMIN IN CHINA, SOUTH KOREA, TAIWAN AND 9 OTHER SOUTHEAST ASIAN COUNTRIES​.‍PHASE 3 PROGRAM FOR IMEGLIMIN IN JAPAN ON TRACK TO BE INITIATED IN Q4 OF CY 2017​.‍RECEIVES FUTURE POTENTIAL DEVELOPMENT MILESTONE PAYMENTS AND SALES-BASED PAYMENTS OF UP TO ¥29.25 BILLION​.  Full Article

Kitasato Institute and Sumitomo Dainippon Pharma signs joint drug discovery research agreement
Tuesday, 24 Oct 2017 04:22am EDT 

Oct 24 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and the Kitasato Institute have signed a joint drug discovery research agreement for infections caused by bacteria with antimicrobial resistance (AMR).  Full Article

R&I affirms Sumitomo Dainippon Pharma's rating at "A" and announces stable outlook -R&I
Tuesday, 3 Oct 2017 05:19am EDT 

Oct 3(Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A" -R&I.Rating outlook stable -R&I.  Full Article

BRIEF-Sumitomo Dainippon Pharma and JCR Pharmaceuticals sign license agreement

* Says it and JCR Pharmaceuticals Co Ltd signed a license agreement on Blood-Brain Barrier Penetration Technology for creation of a therapeutic agent for Central Nervous System Diseases